Despite advances in prevention, cytomegalovirus (CMV) recurrence is an important
challenge in high‐risk organ recipients. The present study prospectively evaluates the …

Given these findings, continuing efforts are underway to determine whether further therapy,
vaccination, or alternative management strategies may improve outcomes in solid-organ …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

Background. Cytomegalovirus (CMV) disease after discontinuation of prophylaxis is a
significant problem for CMV-seronegative recipients of CMV-seropositive organs (donor …

Background. During the contemporary era of antiviral prophylaxis, the impact of delayed-
onset primary cytomegalovirus (CMV) disease on the outcome of kidney transplantation is …

Cytomegalovirus (CMV) is a major cause of morbidity and mortality following solid organ
transplantation (SOT). Two strategies, prophylactic, and preemptive have emerged for the …

Background. The incidence and impact of cytomegalovirus (CMV) disease that occurs
despite CMV prophylaxis among liver transplant recipients have been incompletely defined …

Cytomegalovirus is a significant cause of morbidity and mortality in transplantation.
Controversy exists concerning whether prophylactic or pre‐emptive therapy is the optimal …

During a 38-month period, we studied 320 liver transplants in 283 recipients (202 adults, 81
children). CMV disease was documented in 85 patients (30.0%). The major risk factor for …

Cytomegalovirus (CMV) infection is an important and frequent complication in solid organ
transplant (SOT) recipients. This infection causes direct effects by viral inclusion in the cells …